{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:50:01Z","timestamp":1777218601288,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pazopanib is an oral tyrosine-kinase inhibitor that is approved by the U.S. Food and Drug Administration for treatment of metastatic renal cell carcinoma (mRCC). Pharmacokinetic data have shown that concomitant administration of pazopanib and esomeprazole, a proton pump inhibitor (PPI), leads to decreased area under the curve and thus decreased exposure of pazopanib by 40%. Despite the pharmacokinetic data published to date, the clinical significance and impact on patient outcomes resulting from decreased pazopanib exposure remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>In this retrospective, observational, cohort study, 90 patients with mRCC who either received pazopanib in combination with a PPI or histamine 2 receptor antagonist (H2RA; concurrent PPI\/H2RA group) or who did not take concurrent pH-elevating medications (no PPI\/H2RA group) were compared to determine if there was an impact on progression-free survival (PFS), the primary endpoint, and secondary endpoints, overall survival (OS) and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The differences between the PFS of 9.0 months and OS of 28.0 months for the concomitant PPI\/H2RA group versus 11.0 months and 30.1 months, respectively, for the no PPI\/H2RA group were not statistically significant. Rates of adverse events were similar between the concomitant PPI\/H2RA and no PPI\/H2RA groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Concomitant PPI or H2RA usage was not shown to be associated with a reduction in PFS or OS for patients receiving pazopanib for mRCC, with a similar toxicity profile in each group. Based on the results of this retrospective cohort study and the palliative nature of the treatment of patients with mRCC, clinicians should consider allowing patients to remain on concomitant pazopanib and acid-reducing therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Pazopanib is a preferred category-one first-line treatment for predominant clear cell metastatic renal cell carcinoma (mRCC). However, because of an aging demographic, coupled with patients with mRCC presenting with multiple comorbidities, including symptomatic dyspepsia or gastroesophageal reflux disease, patients are commonly required to take pazopanib concomitantly with a proton pump inhibitor (PPI) or a histamine 2 receptor antagonist (H2RA). Despite earlier pharmacokinetic reports suggesting that an alkaline pH may result in poorer absorption, this institutional retrospective study found no effect on clinical outcomes. These data suggest that concurrent treatment of mRCC with pazopanib and a PPI or H2RA may be safe in everyday practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0578","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T21:16:06Z","timestamp":1519766166000},"page":"686-692","source":"Crossref","is-referenced-by-count":32,"title":["Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Renee K.","family":"McAlister","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Aston","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Pollack","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Chism","sequence":"additional","affiliation":[{"name":"Department of Medicine - Division of Hematology-Oncology, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"2021122510531968500_onco12408-bib-0001","year":"2017"},{"key":"2021122510531968500_onco12408-bib-0002","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122510531968500_onco12408-bib-0003","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122510531968500_onco12408-bib-0004","author":"National Comprehensive Cancer Network"},{"issue":"suppl 5","key":"2021122510531968500_onco12408-bib-0005","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510531968500_onco12408-bib-0006","author":"Ljungberg","year":"2017"},{"key":"2021122510531968500_onco12408-bib-0007","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"New Engl J Med"},{"key":"2021122510531968500_onco12408-bib-0008","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510531968500_onco12408-bib-0009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510531968500_onco12408-bib-0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2021122510531968500_onco12408-bib-0011","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2021122510531968500_onco12408-bib-0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/bega.2001.0184","article-title":"Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician","volume":"15","author":"Huang","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2021122510531968500_onco12408-bib-0013","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2013.06.008","article-title":"An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib","volume":"82","author":"Hilton","year":"2013","journal-title":"Lung Cancer"},{"key":"2021122510531968500_onco12408-bib-0014","volume-title":"Tarceva (R) [package insert]","year":"2016"},{"key":"2021122510531968500_onco12408-bib-0015","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2125.2010.03748.x","article-title":"Erlotinib and pantoprazole: A relevant interaction or not?","volume":"70","author":"Ter Heine","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2021122510531968500_onco12408-bib-0016","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122510531968500_onco12408-bib-0017","volume-title":"Tasigna (R) [package insert]","year":"2017"},{"key":"2021122510531968500_onco12408-bib-0018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/0091270009346061","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"50","author":"Yin","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2021122510531968500_onco12408-bib-0019","volume-title":"Sprycel (R) [package insert]","year":"2017"},{"key":"2021122510531968500_onco12408-bib-0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"2021122510531968500_onco12408-bib-0021","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122510531968500_onco12408-bib-0022","first-page":"499","article-title":"Evaluating medication adherence: Which measure is right for your program?","volume":"6","author":"Fairman","year":"2000","journal-title":"J Manag Care Spec Pharm"},{"key":"2021122510531968500_onco12408-bib-0023","author":"Crowe"},{"key":"2021122510531968500_onco12408-bib-0024","author":"Nau"},{"key":"2021122510531968500_onco12408-bib-0025","year":"2017"},{"key":"2021122510531968500_onco12408-bib-0026","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2021122510531968500_onco12408-bib-0027","author":"U.S. National Library of Medicine"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0578","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/686\/41916606\/oncolo_23_6_686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/686\/41916606\/oncolo_23_6_686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:53:56Z","timestamp":1640429636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/6\/686\/6439756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,2,27]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0578","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2018,2,27]]}}}